Ligand Pharmaceuticals Incorporated (LGND)

Payables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cost of revenue (ttm)	US$ in thousands	37,563	36,390	27,380	17,886	10,535	30,485	41,153	51,845	52,827	43,197	40,490	58,722	62,176	61,931	56,838	33,889	30,419	20,617	17,411	12,172
Payables	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Payables turnover		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

December 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $37,563K ÷ $—K
= —

The payables turnover ratio for Ligand Pharmaceuticals Incorporated is currently unavailable as there is no data provided for accounts payable for any of the periods mentioned in the financial statements. The payables turnover ratio is a measure of how efficiently a company is managing its payments to suppliers. It indicates the number of times a company pays off its average accounts payable balance during a certain period.

Without the necessary data on payables and purchases, it is not possible to calculate the payables turnover ratio. Typically, a high payables turnover ratio suggests that a company is paying off its suppliers quickly, which could indicate good liquidity management. On the other hand, a low payables turnover ratio may indicate that the company is taking longer to pay off its suppliers.

In conclusion, the absence of payables data prevents a comprehensive analysis of Ligand Pharmaceuticals' payables turnover ratio. It would be beneficial for stakeholders to have access to this information to evaluate the company's efficiency in managing its accounts payable.